Sep 9, 2026

AmMax Bio Names Suneel K. Gupta, Ph.D. as Chief Scientific Officer to Advance Novel ADC Portfolio
AMB-104, a potential first-in-class ADC to treat AML, expected to enter the clinic in 2027

Read More Jun 16, 2026

AmMax Bio Names Biopharmaceutical Executive Travis Read as President and Chief Operating Officer

Read More Jun 9, 2026

AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza

New agreement provides AmMax with access to Lonza’s GlycoConnect®, HydraSpace®, and SYNtecan™ linker-payload technologies Agreement to target development of novel antibody-drug conjugates (ADCs) for oncology indications Read More Mar 18, 2025

AmMax Bio Presentation at BIO-Europe Spring 2025

Tuesday, March 18th @ 9:45 AM CET Read More Mar 11, 2025

AmMax Bio Announces Presentation at BIO-Europe Spring 2025

Read More Jan 27, 2025

AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies Read More Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

Collaboration to evaluate monoclonal antibody as first-in-class treatment in this setting Read More Sep 27, 2024

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase

Oncology pipeline led by first-in-class treatment for patients suffering from colorectal cancer with minimal residual disease (CRC MRD) Read More